Talquetamab,Teclistamab,Daratumumab
Janssen
['mmsm']
the objective response rate with the dual bispecific combination was 86.6% across all doses and 96.3% at the recommended phase 2 regimen dose level. #mmsm #asco23 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.